We love to hear from our listeners. Send us a message. In this week's episode of the Business of Biotech -- part two in a four-part series recorded in-person at Catalyst Pharmaceuticals' Miami headquarters -- we're speaking with Daniel Teper, an entrepreneur and most recently, founder and CEO at NAYA Therapeutics. Based in South Florida, NAYA is developing NK-engaging bifunctional antibodies and Astatine-211 radiopharmaceuticals targeting hepatocellular carcinoma. Daniel discusses the company's decentralized manufacturing strategy, the current funding climate for early-stage companies, his plan to conduct clinical trials in China, and what's unique about the South Florida life sciences ecosystem. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter . Get in touch with guest and topic suggestions :
[email protected] Find Ben Comer on LinkedIn : https://www.linkedin.com/in/bencomer/
